Following this, to screen compounds with potential as AD therapeutics while maintaining target specificity, we applied a secondary filtering step that incorporated both predicted binding affinity and predicted CNS-relevant ADMET properties, BBB permeability and P-glycoprotein (Pgp) inhibition/substrate probabilities, critical determinants of CNS drug efficacy and retention. Here, PGP is linked to Alzheimer disease.